Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Szymon Pawlak, Joanna Śliwka, Joanna Kwiatkowska, Arkadiusz Wierzyk, Agnieszka Kuczaj, Piotr Przybyłowski, Tomasz Hrapkowicz
The aim of this study is to analyze the feasibility of performing an isolated heart transplant in patients with severe pulmonary hypertension as a result of restrictive cardiomyopathy. The results present the clinical course from the diagnosis of restrictive cardiomyopathy at the age of 2 until the heart transplant at 8 years old. Initially, the patient was considered for multiorgan transplantation, heart and lungs, due to extremely high pulmonary resistance. However, due to the prolonged waiting period for a donor and the worsening condition of the child, a decision was made to perforate the atrial septum with the implantation of an atrial flow regulator system...
April 19, 2024: Transplantation Proceedings
#22
JOURNAL ARTICLE
Zhiyong Guo, Yao Liu, Qi Ling, Leibo Xu, Tielong Wang, Jiaxing Zhu, Yimou Lin, Xinjun Lu, Wei Qu, Fan Zhang, Zhijun Zhu, Jian Zhang, Zehua Jia, Ping Zeng, Wenjing Wang, Qiang Sun, Qijie Luo, Zemin Hu, Zhouying Zheng, Yingbin Jia, Jian Li, Yujian Zheng, Mengchao Wang, Shaoping Wang, Zemin Han, Sheng Yu, Chuanjiang Li, Shuhua Zhang, Jun Xiong, Feiwen Deng, Ying Liu, Huanwei Chen, Yanfeng Wang, Ling Li, Wenjin Liang, Andrea Schlegel, Nashan Björn, Chao Liu, Shusen Zheng, Xiaoshun He
Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma (HCC) patients is rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICIs therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICIs therapy during the study period. The median post-LT follow up was 8.1 (interquartile range [IQR] 3...
April 18, 2024: American Journal of Transplantation
#23
JOURNAL ARTICLE
Amanda Klein, Luke Kosinski, Alexandre Loupy, Eric Frey, Mark Stegall, Ilkka Helanterä, Kenneth Newell, Herwig-Ulf Meier-Kriesche, Roslyn B Mannon, William E Fitzsimmons
Biopsy-proven acute rejection (BPAR) occurs in approximately 10% of kidney transplant recipients in the first year making superiority trials unfeasible. IBOX, a quantitative composite of eGFR, proteinuria, anti-HLA DSA, and + full/- abbreviated kidney histopathology, is a new proposed surrogate endpoint. BPAR's prognostic ability was compared to iBOX in a pooled cohort of 1534 kidney transplant recipients from four datasets, including two prospective randomized controlled trials. Discrimination analyses showed mean c-statistic differences between both iBOX compared to BPAR of 0...
April 18, 2024: American Journal of Transplantation
#24
JOURNAL ARTICLE
Alessandra Palmisano, Marta D'Angelo, Ilaria Gandolfini, Marco Delsante, Giovanni Maria Rossi, Micaela Gentile, Enrico Fiaccadori, Paolo Cravedi, Umberto Maggiore
INTRODUCTION: It is unclear whether kidney transplant recipients with a biopsy diagnosis as a "borderline" acute T-cell mediated rejection (TCMR) requires the treatment with intravenous (iv) steroids pulse plus/minus intensification of the maintenance therapy (TRT) in comparison with the simple clinical follow-up (F-UP). METHODS: We retrospectively followed a consecutive series of kidney transplant recipients diagnosed with a borderline acute TCMR at biopsy by surveillance or clinical indication for 12 months and compared TRT and F-UP groups...
April 17, 2024: Transplant Immunology
#25
JOURNAL ARTICLE
Thibaut Vaulet, Jasper Callemeyn, Baptiste Lamarthée, Asier Antoranz, Tim Debyser, Priyanka Koshy, Dany Anglicheau, Jill Colpaert, Wilfried Gwinner, Philip F Halloran, Dirk Kuypers, Claire Tinel, Amaryllis Van Craenenbroeck, Elisabet Van Loon, Pierre Marquet, Francesca Bosisio, Maarten Naesens
BACKGROUND: The link between the histology of kidney transplant rejection, especially Antibody-mediated rejection, T cell-mediated rejection and Mixed rejection, and the types of infiltrating immune cells is currently not well charted. Cost and technical complexity of single cell analysis hinder large scale studies of the relationship between cell infiltrate profiles and histological heterogeneity. METHODS: In this cross-sectional study, we assessed the composition of nine intragraft immune cell types by using a validated kidney transplant-specific signature matrix for deconvolution of bulk transcriptomics in three different kidney transplant biopsy datasets (N=403, N=224, N=282)...
April 19, 2024: Journal of the American Society of Nephrology: JASN
#26
JOURNAL ARTICLE
Ursula Reinert, Berthold Seitz, Cristian Munteanu, Loay Daas
BACKGROUND: The aim of this study was to assess the impact of the ratio between the graft and host corneal size (RGH) on postoperative complications, such as immune reactions, re-bubbling rate and endothelial cell loss (ECL) after Descemet membrane endothelial keratoplasty (DMEK). PATIENTS AND METHODS: Retrospectively, 457 patient eyes were included which had undergone surgery between 2016 and 2019 in the Department of Ophthalmology, Saarland University Medical Center in Homburg/Saar using DMEK or triple DMEK, diagnosed as Fuchs' endothelial dystrophy (n = 431), pseudophakic bullous keratopathy (n = 9) and others (n = 17)...
April 19, 2024: Ophthalmologie
#27
REVIEW
Qin Sun, Si-Yuan Song, Jiabao Ma, Danni Li, Yiping Wang, Zhengteng Yang, Yi Wang
In the quest to address the critical shortage of donor organs for transplantation, xenotransplantation stands out as a promising solution, offering a more abundant supply of donor organs. Yet, its widespread clinical adoption remains hindered by significant challenges, chief among them being immunological rejection. Central to this issue is the role of the complement system, an essential component of innate immunity that frequently triggers acute and chronic rejection through hyperacute immune responses. Such responses can rapidly lead to transplant embolism, compromising the function of the transplanted organ and ultimately causing graft failure...
2024: Frontiers in Immunology
#28
JOURNAL ARTICLE
Rhea McArdle, Rebecca Cope, Afzal Chaudhry, Lisa Sharkey, Sarah Peacock
Despite recent advances that have improved outcomes following intestinal transplantation (ITx), achieving long-term patient survival and rejection-free survival is still challenging. Understanding the relevance of pre-transplant human leukocyte antigen (HLA) donor-specific antibody (DSA) in ITx and the immunomodulatory potential of the liver within the allograft is crucial to providing an accurate assessment of pre-transplant immunological risk, which could influence and improve post-transplant outcomes further...
April 18, 2024: International Journal of Immunogenetics
#29
MULTICENTER STUDY
Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak, Michael R Verneris, Donald B Kohn, Sung-Yun Pai, Blachy J Dávila Saldaña, Benjamin Hanisch, Troy C Quigg, Roberta H Adams, Ann Dahlberg, Shanmuganathan Chandrakasan, Hasibul Hasan, Jemily Malvar, Mariah A Jensen-Wachspress, Christopher A Lazarski, Gelina Sani, John M Idso, Haili Lang, Pamela Chansky, Chase D McCann, Jay Tanna, Allistair A Abraham, Jennifer L Webb, Abeer Shibli, Amy K Keating, Prakash Satwani, Pawel Muranski, Erin Hall, Michael J Eckrich, Evan Shereck, Holly Miller, Ewelina Mamcarz, Rajni Agarwal, Satiro N De Oliveira, Mark T Vander Lugt, Christen L Ebens, Victor M Aquino, Jeffrey J Bednarski, Julia Chu, Suhag Parikh, Jennifer Whangbo, Michail Lionakis, Elias T Zambidis, Elizabeth Gourdine, Catherine M Bollard, Michael A Pulsipher
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter study (NCT03475212) for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus...
April 18, 2024: Nature Communications
#30
JOURNAL ARTICLE
Miko Yu, Kristen L King, Lindsey M Maclay, S Ali Husain, Jesse D Schold, Sumit Mohan
Administrative claims data could provide a unique opportunity to identify acute rejection events by use of specific anti-rejection medications and validate rejection data reported to the Organ Procurement Transplant Network (OPTN). This retrospective cohort study examined differences in registry-reported events and those identified via claims data among adult kidney transplant recipients from 2012-2017 using Standard Analysis Files from the United States Renal Data System. Rejection rates, survival estimates, and center-level differences were assessed using each approach...
April 16, 2024: American Journal of Transplantation
#31
JOURNAL ARTICLE
Sandeep Sainathan, John Ryan, Leonardo Mullinari, Pablo Sanchez
OBJECTIVE: Pediatric Heart-lung transplant (HLTX) is performed for endstage congenital heart disease (CHD) with irreversible pulmonary hypertension or non-congenital heart disease (NCHD) with end-stage heart and lung disease. CHD could influence the outcomes of HTLX due to increased complexity of the operation as compared to NCHD. In this study we evaluated the influence of cardiac diagnosis on outcomes of pediatric HTLX. METHODS: The UNOS database (1987-2022) was queried for primary HTLX in patients <18 years...
April 2024: Clinical Transplantation
#32
REVIEW
Christian Hinze, Svjetlana Lovric, Philip F Halloran, Jonathan Barasch, Kai M Schmidt-Ott
The kidney epithelium, with its intricate arrangement of highly specialized cell types, constitutes the functional core of the organ. Loss of kidney epithelium is linked to the loss of functional nephrons and a subsequent decline in kidney function. In kidney transplantation, epithelial injury signatures observed during post-transplantation surveillance are strong predictors of adverse kidney allograft outcomes. However, epithelial injury is currently neither monitored clinically nor addressed therapeutically after kidney transplantation...
April 17, 2024: Nature Reviews. Nephrology
#33
JOURNAL ARTICLE
Evelyn Katy Alvarez-Salazar, Arimelek Cortés-Hernández, Saúl Arteaga-Cruz, Gloria Soldevila
Regulatory T cells (Tregs) play a crucial role in the homeostasis of the immune response. Tregs are mainly generated in the thymus and are characterized by the expression of Foxp3, which is considered the Treg master transcription factor. In addition, Tregs can be induced from naïve CD4+ T cells to express Foxp3 under specific conditions both in vivo (pTregs) and in vitro (iTregs). Both subsets tTregs and pTregs are necessary for the establishment of immune tolerance to self and non-self antigens. Although it has been postulated that iTregs may be less stable compared to tTregs, mainly due to epigenetic differences, accumulating evidence in animal models shows that iTregs are stable in vivo and could be used for the treatment of inflammatory disorders including autoimmune diseases and allogeneic transplant rejection...
April 17, 2024: Journal of Leukocyte Biology
#34
JOURNAL ARTICLE
Rui Zheng, Xinxin Wu, Si Li, Xinhao Chen, Dan Yan, Jigang He
Immunoregulation and indoleamine 2,3-dioxygenase 1 (IDO1) play pivotal roles in the rejection of allogeneic organ transplantation. This study aims to elucidate the immune-related functional mechanisms of exosomes (Exos) derived from bone marrow-derived mesenchymal stem cells (BMSCs) overexpressing IDO1 in the context of allogeneic heart transplantation (HTx) rejection. A rat model of allogeneic HTx was established. Exos were extracted after transfection with oe-IDO1 and oe-NC from rat BMSCs. Exos were administered via the caudal vein for treatment...
2024: Cell Transplantation
#35
JOURNAL ARTICLE
Mitra Ghasemi, Athar Talebi, Ali Ghanbari, Parisa Hayat, Behpour Yousefi, Moslem Mohammadi, Mahmood Abedinzade, Nooshin Ahmadirad, Sam Zarbakhsh
OBJECTIVES: Despite the many benefits of mesenchymal stem cell (MSC) transplantation for tissue regeneration, there are some limitations to using them, including the high costs, applying invasive procedures, the possibility of transplant rejection, and cell malignancy. This study aimed to investigate the effect of secretions of bone marrow stromal cells (BMSCs) with the cell-free strategy on damaged sciatic nerve with an emphasis on the role of apoptosis and the expression of myelin protein zero (MPZ) and nerve growth factor (NGF) proteins...
2024: Iranian Journal of Basic Medical Sciences
#36
JOURNAL ARTICLE
Carla Ramirez-Amoros, Maria San Basilio, Virginia Amesty, Susana Rivas, Roberto Lobato, Carlota Fernandez-Camblor, Pedro Lopez-Pereira, Maria Jose Martinez-Urrutia
BACKGROUND: Renal transplantation is currently the best treatment option for patients with end-stage renal disease. However, the use of kidneys from donors under 6 years of age as a possibility to increase the organ pool in pediatric recipients remains a controversial matter. We aimed to investigate whether donor age is associated to the long-term functionality of the renal graft. Likewise, we analyzed the adaptation of the graft to the ascending functional requirements in the pediatric patient...
May 2024: Pediatric Transplantation
#37
REVIEW
Harit Thongwitokomarn, Kajohnsak Noppakun, Romanee Chaiwarith, Siriporn C Chattipakorn, Nipon Chattipakorn
Kidney transplantation is a highly effective treatment for end-stage kidney disease. However, allograft rejection remains a significant clinical challenge in kidney transplant patients. Although kidney allograft biopsy is the gold-standard diagnostic method, it is an invasive procedure. Since the current monitoring methods, including screening of serum creatinine and urinary protein, are not of sufficient sensitivity, there is a need for effective post-transplant monitoring to detect allograft rejection at an early stage...
April 2024: Clinical Transplantation
#38
JOURNAL ARTICLE
Parul Chawla Gupta, Bijaya K Padhi, Hashem Abu Serhan, Arkadiusz Dziedzic, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Abhay M Gaidhane, Neelima Kukreti, Sarvesh Rustagi, Prakasini Satapathy
INTRODUCTION: The COVID-19 pandemic has initiated an unparalleled global vaccination campaign, raising concerns about the vaccine's effects on various health conditions, including the risk of corneal transplant rejection. This systematic review aimed to identify the relationship between COVID-19 vaccination and rejection of corneal transplant, filling a significant gap in the existing medical literature. METHODS: A literature search was performed across multiple databases up to February 12, 2024, to identify studies evaluating the risk of corneal transplant rejection post-COVID-19 vaccination...
April 16, 2024: Ophthalmology and Therapy
#39
JOURNAL ARTICLE
Ahmed Daoud, Karim Soliman, Maria Aurora Posadas Salas, Genta Uehara, Sakshi Vaishnav, Wisit Cheungpasitporn, Michael J Casey
AIM: Kidney transplant recipients (KTRs), due to their immunosuppressed status, are potentially more susceptible to both the severe effects of COVID-19 and complications in their transplanted organ. The aim of this study is to investigate whether COVID-19 infection increases the risk of rejection in kidney transplant recipients (KTRs). METHODS: This study involved a detailed literature review, conducted using PubMed, with the search being completed by September 7th, 2023...
December 2024: Renal Failure
#40
JOURNAL ARTICLE
Sarah Nikiforow, Jennifer S Whangbo, Ran Reshef, Donald E Tsai, Nancy J Bunin, Rolla F Abu-Arja, Kris Michael Mahadeo, Wen-Kai Weng, Koen Van Besien, David Loeb, Sunita D Nasta, Eneida R Nemecek, Weizhi Zhao, Yan Sun, Faith C Galderisi, Justin Wahlstrom, Aditi Mehta, Laurence Isabelle Gamelin, Rajani Dinavahi, Susan E Prockop
Patients with Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in whom initial treatment fails have few options and historically low median overall survival (OS) of 0.7 months following allogeneic hematopoietic cell transplant (HCT) and 4.1 months following solid organ transplant (SOT). Tabelecleucel is an off-the-shelf, allogeneic EBV-specific cytotoxic T-lymphocyte immunotherapy for EBV+ PTLD. Previous single-center experience showed responses in patients with EBV+ PTLD following HCT or SOT...
April 16, 2024: Blood Advances
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
